Pipeline
Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Partner
oNKord®
Inaleucel
AML
NK Cell
Phase II
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
AML
NK Cell
II
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
MM
NK Cell
Phase I
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
MM
NK Cell
I
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
Melanoma
NK Cell
Development
Glycostem
oNKord®
Inaleucel
Melanoma
NK Cell
DEV
TBA
Glycostem
Inaleucel
N/D
Combination Therapy
Development
Glycostem
oNKord®
Inaleucel
N/D
Combination Therapy
DEV
TBA
Glycostem
viveNK™
GTA103
Glioblastoma
CAR-NK
Development
inno.N (Japan and Korea)
viveNK™
GTA103
Glioblastoma
CAR-NK
DEV
TBA
inno.N (Japan and Korea)
GTA103
N/A
CAR-NK
Development
Glycostem
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
Glycostem
GTA201
N/D
TCR-NK
Development
Glycostem
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Glycostem
Therapy
Phase
Partner
oNKord®
Inaleucel
AML
NK Cell
Phase II
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
AML
NK Cell
II
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
MM
NK Cell
Phase I
medac (EU)
inno.N (Japan and Korea)
oNKord®
Inaleucel
MM
NK Cell
I
2025
medac (EU)
inno.N (Japan and Korea)
Inaleucel
Melanoma
NK Cell
Development
Glycostem
oNKord®
Inaleucel
Melanoma
NK Cell
DEV
TBA
Glycostem
Inaleucel
N/D
Combination Therapy
Development
Glycostem
oNKord®
Inaleucel
N/D
Combination Therapy
DEV
TBA
Glycostem
viveNK™
GTA103
Glioblastoma
CAR-NK
Development
inno.N (Japan and Korea)
viveNK™
GTA103
Glioblastoma
CAR-NK
DEV
TBA
inno.N (Japan and Korea)
GTA103
N/A
CAR-NK
Development
Glycostem
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
Glycostem
GTA201
N/D
TCR-NK
Development
Glycostem
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Glycostem